Epoch Investment Partners Inc. Sells 222,601 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Epoch Investment Partners Inc. lowered its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 99.6% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 967 shares of the medical equipment provider’s stock after selling 222,601 shares during the quarter. Epoch Investment Partners Inc.’s holdings in Intuitive Surgical were worth $386,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Intuitive Surgical by 1.6% in the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after purchasing an additional 493,126 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Intuitive Surgical by 1.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock valued at $5,726,102,000 after purchasing an additional 272,741 shares during the last quarter. Capital World Investors lifted its position in Intuitive Surgical by 1.0% in the first quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock valued at $2,907,079,000 after purchasing an additional 73,634 shares during the last quarter. Edgewood Management LLC lifted its position in Intuitive Surgical by 7.9% in the fourth quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock valued at $1,731,016,000 after purchasing an additional 374,667 shares during the last quarter. Finally, Fisher Asset Management LLC lifted its position in Intuitive Surgical by 2.0% in the fourth quarter. Fisher Asset Management LLC now owns 4,494,373 shares of the medical equipment provider’s stock valued at $1,516,222,000 after purchasing an additional 88,977 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Insider Activity at Intuitive Surgical

In related news, EVP Myriam Curet sold 2,818 shares of the stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $1,291,010.34. Following the sale, the executive vice president now directly owns 298 shares of the company’s stock, valued at $136,522.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, EVP Myriam Curet sold 2,818 shares of the stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $1,291,010.34. Following the sale, the executive vice president now directly owns 298 shares of the company’s stock, valued at $136,522.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Robert Desantis sold 376 shares of the stock in a transaction on Monday, April 29th. The shares were sold at an average price of $375.39, for a total value of $141,146.64. Following the sale, the executive vice president now directly owns 5,507 shares in the company, valued at $2,067,272.73. The disclosure for this sale can be found here. Insiders have sold 13,358 shares of company stock valued at $5,592,694 over the last ninety days. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Stock Up 1.0 %

Shares of NASDAQ ISRG traded up $4.56 during trading on Friday, reaching $441.30. The company had a trading volume of 1,196,597 shares, compared to its average volume of 1,795,967. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $468.78. The stock has a market cap of $156.82 billion, a PE ratio of 79.66, a P/E/G ratio of 4.86 and a beta of 1.39. The business’s 50-day moving average is $427.82 and its 200 day moving average is $398.55.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. During the same period in the prior year, the firm posted $1.18 earnings per share. The company’s quarterly revenue was up 14.5% on a year-over-year basis. On average, analysts anticipate that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Robert W. Baird upped their target price on Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a report on Friday, July 19th. Barclays upped their target price on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a report on Thursday, July 18th. Jefferies Financial Group upped their target price on Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a report on Friday, April 19th. Evercore ISI decreased their target price on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating for the company in a report on Friday, July 19th. Finally, JPMorgan Chase & Co. upped their target price on Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a report on Friday, July 19th. Six research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $438.74.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.